Skip to main content
Fig. 1 | BMC Health Services Research

Fig. 1

From: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis

Fig. 1

Quarterly purchases of the biosimilars Inflectra®, Basaglar®, and Grastofil®. Percent of Total Purchases represents the percent of time the biosimilars Basaglar®, Grastofil®, and Inflectra® were purchased when considering all purchases for both the biosimilar (Basaglar®, Grastofil®, and Inflectra®) and originator drugs (Lantus®, Neupogen®, and Remicade®)

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us